- Home
- TVGN vs KRRO Comparison
TVGN vs KRRO Comparison
Compare TVGN & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TVGN
- KRRO
- Stock Information
- Founded
- TVGN 2020
- KRRO 2014
- Country
- TVGN United States
- KRRO United States
- Employees
- TVGN N/A
- KRRO N/A
- Industry
- TVGN Blank Checks
- KRRO Biotechnology: Pharmaceutical Preparations
- Sector
- TVGN Finance
- KRRO Health Care
- Exchange
- TVGN Nasdaq
- KRRO Nasdaq
- Market Cap
- TVGN 193.1M
- KRRO 209.6M
- IPO Year
- TVGN N/A
- KRRO 2019
- Fundamental
- Price
- TVGN $1.09
- KRRO $15.56
- Analyst Decision
- TVGN Strong Buy
- KRRO Strong Buy
- Analyst Count
- TVGN 1
- KRRO 7
- Target Price
- TVGN $10.00
- KRRO $90.67
- AVG Volume (30 Days)
- TVGN 1.6M
- KRRO 103.1K
- Earning Date
- TVGN 05-28-2025
- KRRO 05-07-2025
- Dividend Yield
- TVGN N/A
- KRRO N/A
- EPS Growth
- TVGN N/A
- KRRO N/A
- EPS
- TVGN N/A
- KRRO N/A
- Revenue
- TVGN N/A
- KRRO $4,821,000.00
- Revenue This Year
- TVGN N/A
- KRRO N/A
- Revenue Next Year
- TVGN N/A
- KRRO $55.56
- P/E Ratio
- TVGN N/A
- KRRO N/A
- Revenue Growth
- TVGN N/A
- KRRO N/A
- 52 Week Low
- TVGN $0.26
- KRRO $11.13
- 52 Week High
- TVGN $3.09
- KRRO $98.00
- Technical
- Relative Strength Index (RSI)
- TVGN 53.95
- KRRO 45.62
- Support Level
- TVGN $1.01
- KRRO $13.40
- Resistance Level
- TVGN $1.09
- KRRO $22.15
- Average True Range (ATR)
- TVGN 0.08
- KRRO 2.47
- MACD
- TVGN 0.02
- KRRO 0.07
- Stochastic Oscillator
- TVGN 81.02
- KRRO 24.69
About TVGN Tevogen Bio Holdings Inc. Common Stock
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.
About KRRO Korro Bio Inc.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.